Orr

Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021
California Institute for Regenerative Medicine, Clinical trial, Woman, Chief executive officer, UC, Webcast, U.S. Securities and Exchange Commission, Forward-looking statement, Senior, Orr, CLL, Progression-free survival, Asco, Corporate development, Breast cancer, MCL, PFS, Private Securities Litigation Reform Act, Regenerative medicine, Venetoclax, Cancer, Rule, Patient, CRS, CIRM, GLOBE, ROR1, Mantle cell lymphoma, ETS, University of California, San Diego, Hematological Cancer Research Investment and Education Act, Paclitaxel, OS, Risk, Chronic lymphocytic leukemia, Aplastic anemia, Nasdaq, Research, Drug development, BTK, Therapy, Ewing's sarcoma, California, CR, Disease, Pharmaceutical industry, Communications satellite

ET

Key Points: 
  • ET
    SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the second quarter of 2021.
  • ET to provide a business update and discuss its second quarter of 2021 financial results.
  • Our grant revenue was $0.9 million for the second quarter ended June 30, 2021.
  • Our total operating expenses for the second quarter ended June 30, 2021 were $8.6 million, including $1.8 million in non-cash stock based compensation.

Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights

Retrieved on: 
Thursday, August 5, 2021
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Company, Lung, Cancer, RDE, Chief executive officer, Research, List of life sciences, NT5E, Investment, Orr, Population, Pancreatic cancer, PFS, IND, Partnership, TKI, Autumn, Patient, Board, Docetaxel, Data, Non-small-cell lung carcinoma, New York Stock Exchange, Prostate, Prostate cancer, AstraZeneca, MCRPC, D, NP, Board of directors, Safety, Colon, Conference, Pharmaceutical industry, Medical imaging

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights.
  • Based on this dataset, Arcus and Gilead will continue preparations for additional Phase 3 studies of dom-based combinations.
  • Results from the interim analysis for ARC-7 are expected to be submitted later this year for a presentation in 4Q21 or in 1H22.
  • Management will host a conference call today, August 5, 2021 to discuss second quarter 2021 financial results and recent corporate highlights.

Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates

Retrieved on: 
Thursday, August 5, 2021
IOV, Health, Patent, IL-2, Method, PD-L1, Manuscript, Cryopreservation, Cervical cancer, Cancer, Non-small-cell lung carcinoma, SAN, Pembrolizumab, Poster, Safety, American Society of Clinical Oncology, Annual general meeting, Transcription activator-like effector nuclease, Asco, PBL, Metastasis, Melanoma, Annual report, Private Securities Litigation Reform Act, Food and Drug Administration, Research, Interim, Security (finance), Risk, Investor, Orr, Population, Technology, Growth, Perception, Til, Food, Nasdaq, GLOBE, U.S. Securities and Exchange Commission, Investment, American Journal of Clinical Oncology, Programmed cell death protein 1, Journal, Lymphatic system, Dor, Patient, COVID-19, Society, BLA, Information, Forward-looking statement, Pharmaceutical industry, Medical imaging, Animal

SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.

Key Points: 
  • SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.
  • Research and development expenses were$62.1 millionfor the second quarter endedJune 30, 2021, an increase of$12.8 millioncompared to$49.3 millionfor the second quarter endedJune 30, 2020.
  • General and administrative expenses were$19.3 millionfor the second quarter endedJune 30, 2021, an increase of$5.0 millioncompared to$14.4 millionfor the second quarter endedJune 30, 2020.
  • Iovance will host a conference call today at4:30 p.m. ETto discuss the second quarter 2021 financial results and corporate updates.

Radius Health, Inc.: Second Quarter and Year-to-Date Results

Retrieved on: 
Thursday, August 5, 2021
Media relations, Irritability, Fracture, Safety, Food, GAAP, Caregiver, Osteoporosis, Annual report, Private Securities Litigation Reform Act, PWS, CDK, Genetic disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Elacestrant, Metabolic syndrome, Diabetes, Obesity, Security (finance), Investor, Woman, Orr, Progression-free survival, Anxiety, Estrogen receptor alpha, Radius, Administration, Vaccine, Mortality, Partnership, Endocrinology, Prader–Willi syndrome, Atom (Web standard), SEC, Company, BMD, Table, Man, U.S. Securities and Exchange Commission, History, Breast cancer, Wearable, Dor, Mission statement, Patient, PFS, Selective estrogen receptor degrader, COVID-19, Abaloparatide, Polyphagia, Bone fracture, Risk, Disease, NDA, Goal, International, Pharmaceutical industry, Dietary supplement

The full text of the announcement and financial results will also be available on the Companys website.

Key Points: 
  • The full text of the announcement and financial results will also be available on the Companys website.
  • The full text of the announcement and financial results will also be available on the Companys website.
  • Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions.
  • Radius is initially targeting Prader-Willi Syndrome (PWS) and anticipates initiating a seamless pivotal Phase 2/3 study for patients with PWS in the fourth quarter of 2021 or first quarter of 2022.

eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

Retrieved on: 
Wednesday, August 4, 2021
Biomarkers, Biology, Branches of biology, Clinical medicine, KRAS, Non-small-cell lung carcinoma

eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer (NSCLC).

Key Points: 
  • eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer (NSCLC).
  • The Phase 2a expansion cohorts will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of zotatifin in subjects with biomarker-positive solid tumor malignancies, including ER+ breast cancer and KRAS-mutant NSCLC.
  • eFFECTOR expects to present additional data from the Phase 1 dose escalation portion of the trial, as well as preliminary response data from Phase 2a expansion cohorts, at a medical conference in 2022.
  • Zotatifin, eFFECTORs inhibitor of eIF4A, is currently being evaluated in a Phase 2a clinical trial in patients with breast cancer and KRAS-mutant NSCLC.

CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health care, Biotechnology, Health sciences, Immunology, Antineoplastic drugs, Bristol-Myers Squibb, Ipilimumab, Antibody-drug conjugate, AbbVie, Biopharmaceutical

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the publication of three articles in peer-reviewed journals on pacmilimab (CX-072), the Company’s wholly-owned conditionally activated antibody directed against PD-L1 currently being developed in combination with praluzatamab ravtansine (CX-2009) for the treatment of triple-negative breast cancer (TNBC).

Key Points: 
  • Pacmilimab+ipilimumab was administered intravenously every 3 weeks for four cycles, followed by pacmilimab administered every 2 weeks as monotherapy.
  • We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029).

Jeremy Orr, MPAS, PA-C, is recognized by Continental Who's Who

Retrieved on: 
Monday, May 24, 2021
Orr

With more than 20 years of wide-ranging experience, Mr. Orr is highly adept at patient care.

Key Points: 
  • With more than 20 years of wide-ranging experience, Mr. Orr is highly adept at patient care.
  • After he obtained his initial bachelor's degree, he served for the U.S. Army National Guard in 2005, spending time in Iraq medical departments.
  • For his dedication and successes during his service, he was bestowed various commendations and achievement awards.
  • Mr. Orr dedicates this honorable recognition to Mark Depman, MD, Jarid Mashkuri, MD, Beth Carriere, PA, and Amy Dennis, FNP.

TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and Venetoclax

Retrieved on: 
Wednesday, April 21, 2021
Chemical compounds, Organic compounds, Health sciences, Clinical research, Medical statistics, Antineoplastic drugs, Orphan drugs, Breakthrough therapy, Venetoclax, Clinical endpoint, Orr

We look forward to presenting the results of the Phase 2 portion of this study at a future medical meeting.

Key Points: 
  • We look forward to presenting the results of the Phase 2 portion of this study at a future medical meeting.
  • We are further encouraged by the strong interest of new trial sites to participate in the Phase 3 portion of the trial.
  • The primary endpoint of the trial is overall response rate (ORR) and Complete Response (CR) rate.
  • The primary objective of the trial is to evaluate the safety of venetoclax after U2 induction.

Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)

Retrieved on: 
Friday, February 26, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Incyte, Medical terminology, Medicine, Response Evaluation Criteria in Solid Tumors, Orr, Response rate, Health sciences, Life sciences, POD1UM-202, POD1UM, Retifanlimab, Incyte

The European Medicines Agencys (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process.

Key Points: 
  • The European Medicines Agencys (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process.
  • The primary endpoint is objective response rate (ORR) as determined by independent central review using RECIST v1.1.
  • In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.
  • In 2019, Incyte and Zai Lab announced a collaboration and license agreement for the development and commercialization of retifanlimab in Greater China.

ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma

Retrieved on: 
Monday, December 7, 2020
Medical specialties, Medicine, Non-Hodgkin lymphoma, Branches of biology, Indolent lymphoma, Response rate, Lymphoma, Orr, Aggressive lymphoma

In response-evaluable patients (n=10) who received ALX148 at 15 mg/kg QW, the objective response rate (ORR) was 70.0%.

Key Points: 
  • In response-evaluable patients (n=10) who received ALX148 at 15 mg/kg QW, the objective response rate (ORR) was 70.0%.
  • In response-evaluable patients (n=22) who received ALX148 at 10 mg/kg QW, the ORR was 40.9%.
  • The ORR was 33.3% in patients (n=15) with aggressive lymphoma and 57.1% in patients (n=7) with indolent lymphoma.
  • Investor Contact: Peter Garcia Chief Financial Officer, ALX Oncology (650) 466-7125 Ext.